🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "huge turning point" in the battle against increasingly resistant strains of the bacteria, according to researchers.

A Global Health Concern

Gonorrhoea infections are escalating worldwide, with figures suggesting over 82 million infections each year. Especially elevated rates are reported in the African continent and nations within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. Within England, cases have reached a historical peak, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an important and timely development in the context of growing infection rates, increasing antimicrobial resistance and the extremely scarce therapeutic options currently available.”

Health officials are particularly alarmed about the surge in drug-resistant strains. The global health body has designated it as a "priority pathogen". A tracking program found that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Therapies Secure Authorization

One new antibiotic, marketed under the name Nuzolvence, was approved by the American regulatory agency in December for use against gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Scientists hope that targeted use of this new drug will help hinder the development of resistance.

Another new antibiotic, originating from the drugmaker GSK, was also approved in close succession. This treatment, which is also used to treat urinary tract infections, was demonstrated in studies to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin stemmed from a unique collaborative effort for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm Innoviva to develop it.

“This milestone represents a huge turning point in the therapy of highly resistant gonorrhoea, which until now has been evolving faster than antibiotic development.”

Research Study Results and Global Access

As per data released by a major medical journal, the new drug cured more than 90% of cases of the STI. This puts it on an equal footing with the typical regimen, which uses an injection and a pill. The trial involved hundreds of patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, GARDP has the rights to make available and distribute the drug in many developing nations.

Doctors on the front lines have voiced hope. Access to a easy-to-administer therapy such as this is described as a "revolutionary step" for public health efforts. This is viewed as crucial to reduce the burden of the illness for people and to prevent the spread of extremely resistant gonorrhoea worldwide.